Navigation Links
Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
Date:10/19/2010

EAST NORRITON, Pa., Oct. 19 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that it has appointed Richard E. Kuntz, MD, M.Sc., Senior Vice President and Chief Scientific, Clinical and Regulatory Officer of Medtronic, Inc. (NYSE: MDT), to its Board of Directors.

In his role at Medtronic, Dr. Kuntz oversees the company's global regulatory affairs, health policy and reimbursement, clinical research activities, ventures and new therapies, strategy and innovation, corporate development, and acquisitions, integrations and divestitures functions.  Prior to joining Medtronic in 2005, he was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute, a university-based contract research organization which coordinates National Institutes of Health and industry clinical trials with the United States Food and Drug Administration. Dr. Kuntz has directed over 100 multicenter clinical trials and has authored more than 200 original publications.  He offers a diversified healthcare background and maintains a deep interest in traditional and alternative clinical trial design as well as biostatistics.

"We are very pleased to welcome Dr. Kuntz to Tengion's Board of Directors," said Steven Nichtberger, M.D., president and chief executive officer of Tengion. "Dr. Kuntz offers demonstrated expertise in a broad spectrum of disease areas, including clinical development of both pharmaceuticals and medical devices.  Rick's diverse healthcare background and demonstrated leadership in the management of clinical research activities will be invaluable as Tengion continues to develop its Neo-Urinary Conduit and Neo-Kidney Augment product candidates for patients with bladder cancer and chronic kidney disease, respectively. &
'/>"/>

SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Omeros Appoints David A. Mann to its Board of Directors
11. RainDance Technologies Appoints Olex Vice President, System Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2014)... The “Fluid Management & Visualization Systems ... market with an analysis and forecast of value ... fluid warming and waste management. Along with this, ... systems by applications and regions are also discussed ... at $19,285.5 million in 2013 and is expected ...
(Date:11/15/2014)... The redesigned ActiGraph Link expands upon ... measurement platform with a rich feature set that ... new channels of sensor data captured by a ... Smart technology, the ActiGraph Link supports wireless heart ... ActiGraph’s cloud-based Study Admin platform, giving academic and ...
(Date:11/15/2014)... The "Operating Room Management Market by Product ... Preoperative, operating room Scheduling), by Component (Software, Services), ... to 2019.” defines and segments the operating room ... value by product, such as data management, anesthesia, ... and volumes of operating room management market by ...
(Date:11/15/2014)... 2014 Algenol Biofuels will present at CleanEquity Monaco ... of Monaco . Logo - ... annual invitation-only event hosted by Innovator Capital, the ... partners and sponsors include Prince Albert II of ... University, PR Newswire, the Monte-Carlo SBM, Oceanographic Museum of ...
Breaking Biology Technology:Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 2Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 4ActiGraph Launches GT9X Link Activity Monitor 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Algenol Biofuels Selected to Present at CleanEquity Monaco 2015 2
... Nov. 7 Interleukin Genetics,Inc. (Amex: ILI ), ... and genetic tests for sale to the,emerging personalized health ... 30, 2007. The Company recorded revenue of $2.6 ... million for third quarter ended September 30,2006, a 92% ...
... Function and Tissue Preservation ... in Spinal Cord Injury Model, SAN DIEGO, Nov. ... today the presentation of preclinical data from,its ZFP Therapeutic(TM) ... Meeting of the Society for Neuroscience. A statistically,significant effect ...
... Nov. 7 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... of anti-adhesion, tissue repair and drug delivery,products, announced ... registration,statement with the Securities and Exchange Commission (SEC) ... SyntheMed to sell, from time to,time, up to ...
Cached Biology Technology:Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 2Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 3Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 4Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 5Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 6Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 2Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 3Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 4Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 5SyntheMed Files Universal Shelf Registration 2
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... Nov. 4, 2014   Neurotechnology , a ... that the latest version of its fingerprint matching ... Ongoing MINEX evaluation organized by NIST. The ... using the INCITS 378 fingerprint standard template format. ... public tenders in the United States ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... who study HIV are facing a troubling consequence of their ... patients almost normal life expectancy. However, those same drugs will ... form that eludes current treatments. With a new $3.4 ... of Missouri is leading a team of researchers who want ...
... in the eye often are fatal. Now, scientists at Washington ... identified a mutated gene in melanoma tumors of the eye ... is published in the advance online edition of Nature ... SF3B1," says senior author Anne Bowcock, PhD, professor of genetics. ...
... TEMPE, Ariz.---Arizona State University,s Biodesign Institute has announced ... enters the next phase of a multi-million-dollar, multi-institutional ... rapidly assess an individual,s exposure to radiation in ... project enters a $9.33 million contract option as ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3Gene in eye melanomas linked to good prognosis 2ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose 2
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
... a fluorescein-conjugated jetSI-ENDO (excitation ... 520 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... for high efficiency siRNA delivery ... reagent proven to work effectively ... cell types. Results in silencing ... target gene expression. One step, ...
Biology Products: